Skip to main content

Advertisement

SpringerLink
Log in

Involvement of spleen is associated with shorter survival in patients with angioimmunoblastic T cell lymphoma

  • Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The prognosis of patients with angioimmunoblastic T cell lymphoma (AITL) remains dismal, with their 5-year overall survival (OS) and progression-free survival (PFS) rates of 32–41% and 18–38%, respectively. Spleen involvement occurs in a proportion of patients with AITL. But still, it is unclear whether spleen involvement impacts the prognosis of AITL patients. In this study, we aim to establish new prognostic indicators for the identification of high-risk patients to draft optimal treatment regimens.

Methods

We collected and counted the clinical data of 54 patients with AITL treated with CHOP-based first-line chemotherapy regimen between 2010 and 2021 at Hubei Cancer Hospital and Hunan Cancer Hospital. In addition, all patients received PET-CT scan prior to receiving treatment. We performed univariate and multivariate analyses to assess the predictive role of tumor characteristics, laboratory, and radiographic data for the prognosis of AITL.

Results

We observed that PFS and OS are worse in patients with high ECOG scores, spleen involvement, and low serum albumin levels in patients with AITL. In univariate analysis, stage (HR 3.515 [1.142–10.822], p = 0.028) and spleen involvement (HR 8.378 [1.085–64.696, p = 0.042) were correlated with PFS in patients with AITL. Besides, stage (HR 3.439 [1.108–10.674], p = 0.033) and spleen involvement (HR 11.002 [1.420–85.254], p = 0.022) were significantly correlated with OS. Consistently, spleen involvement was correlated with OS (HR 16.571 [1.350–203.446], p = 0.028) and PFS (HR 10.905 [1.037–114.690], p = 0.047) in AITL patients in a multivariate analysis.

Conclusion

This study demonstrates that spleen involvement might be used as a prognostic indicator for AITL patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The datasets generated and/or analyzed during the study are available upon the reasonable request of the corresponding author.

References

  • Advani RH, Skrypets T, Civallero M, Spinner MA, Manni M, Kim WS, Shustov AR, Horwitz SM, Hitz F, Cabrera ME et al (2021) Outcomes and prognostic factors in angioimmunoblastic T cell lymphoma: final report from the international T cell Project. Blood 138(3):213–220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ et al (2022) Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T cell therapy. Blood Adv 6(9):2867–2871

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Albano D, Dondi F, Bertagna F, Treglia G (2022) The role of [(68)Ga]Ga-pentixafor PET/CT or PET/MRI in lymphoma: a systematic review. Cancers (basel) 14(15):3814

    Article  CAS  PubMed  Google Scholar 

  • Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, de Souza CA, Gabus R, Zoppegno L, Zoppegno L, Milone J et al (2012) T cell lymphomas in South America and Europe. Rev Bras Hematol Hemoter 34(1):42–47

    Article  PubMed  PubMed Central  Google Scholar 

  • Cesta MF (2006) Normal structure, function, and histology of the spleen. Toxicol Pathol 34(5):455–465

    Article  PubMed  Google Scholar 

  • Chiba S, Sakata-Yanagimoto M (2020) Advances in understanding of angioimmunoblastic T cell lymphoma. Leukemia 34(10):2592–2606

    Article  PubMed  PubMed Central  Google Scholar 

  • Eladl AE, Shimada K, Suzuki Y, Takahara T, Kato S, Kohno K, Elsayed AA, Wu CC, Tokunaga T, Kinoshita T et al (2020) EBV status has prognostic implication among young patients with angioimmunoblastic T cell lymphoma. Cancer Med 9(2):678–688

    Article  CAS  PubMed  Google Scholar 

  • Federico M, Rudiger T, Bellei M, Nathwani BN, Luminari S, Coiffier B, Harris NL, Jaffe ES, Pileri SA, Savage KJ et al (2013) Clinicopathologic characteristics of angioimmunoblastic T cell lymphoma: analysis of the international peripheral T cell lymphoma project. J Clin Oncol 31(2):240–246

    Article  CAS  PubMed  Google Scholar 

  • Gaulard P, de Leval L (2011) Follicular helper T cells: implications in neoplastic hematopathology. Semin Diagn Pathol 28(3):202–213

    Article  PubMed  PubMed Central  Google Scholar 

  • Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, Greiner TC, Smith L, Guo S, Wilcox RA et al (2014) Gene expression signatures delineate biological and prognostic subgroups in peripheral T cell lymphoma. Blood 123(19):2915–2923

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li J, Zhao M, Yuan L, Liu Y, Ma N (2022) Correlation and influencing factors of SUVmax and Ki-67 in non-Hodgkin lymphoma. Zhongguo Shi Yan Xue Ye Xue Za Zhi 30(1):136–140

    PubMed  Google Scholar 

  • Lunning MA, Vose JM (2017) Angioimmunoblastic T cell lymphoma: the many-faced lymphoma. Blood 129(9):1095–1102

    Article  CAS  PubMed  Google Scholar 

  • Mourad N, Mounier N, Briere J, Raffoux E, Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A et al (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T cell lymphoma treated within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trials. Blood 111(9):4463–4470

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, Gazzola A, Gloghini A, Righi S, Rossi M et al (2007) Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res 67(22):10703–10710

    Article  CAS  PubMed  Google Scholar 

  • Rossi C, Tosolini M, Gravelle P, Pericart S, Kanoun S, Evrard S, Gilhodes J, Franchini DM, Amara N, Syrykh C et al (2022) Baseline SUVmax is related to tumor cell proliferation and patient outcome in follicular lymphoma. Haematologica 107(1):221–230

    Article  CAS  PubMed  Google Scholar 

  • Solal-Celigny P (2006) Follicular lymphoma international prognostic index. Curr Treat Options Oncol 7(4):270–275

    Article  PubMed  Google Scholar 

  • St-Pierre F, Broski SM, LaPlant BR, Ristow K, Maurer MJ, Macon WR, Habermann TM, Ansell SM, Thompson CA, Micallef INM et al (2019) Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. Am J Hematol 94(7):786–793

    CAS  PubMed  Google Scholar 

  • Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, Hashimoto C, Tamura K, Sato K, Ishigatsubo Y (2012) Prognostic impact of extranodal involvement in diffuse large B cell lymphoma in the rituximab era. Cancer 118(17):4166–4172

    Article  PubMed  Google Scholar 

  • Timmins MA, Wagner SD, Ahearne MJ (2020) The new biology of PTCL-NOS and AITL: current status and future clinical impact. Br J Haematol 189(1):54–66

    Article  PubMed  Google Scholar 

  • Vose J, Armitage J, Weisenburger D, International TCLP (2008) International peripheral T cell and natural killer/T cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26(25):4124–4130

    Article  PubMed  Google Scholar 

  • Zanoni L, Mattana F, Calabro D, Paccagnella A, Broccoli A, Nanni C, Fanti S (2021) Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma. Eur J Radiol 141:109793

    Article  PubMed  Google Scholar 

  • Zhang C, Mi L, Wu M, Liu W, Ma H, Ren J, Zhao L, Wang X, Song Y, Zhu J (2022) Angioimmunoblastic T cell lymphoma: treatment strategies and prognostic factors from a retrospective multicenter study in China. Leuk Lymphoma 63(5):1152–1159

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported, in part, by grants from the Beijing CSCO clinical oncology Research Foundation.

Author information

Author notes

  1. Yingdan Huang and Ruolan Zeng have contributed equally to this work.

Authors and Affiliations

  1. Department of Lymphoma Medicine, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430079, China

    Yingdan Huang, Chang Xue, Qing Huang, Ding Yu & Huijing Wu

  2. Department of Lymphoma and Hematology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, 410013, China

    Ruolan Zeng & Hui Zhou

  3. Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, 430062, China

    Liang Shao

Authors
  1. Yingdan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ruolan Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chang Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qing Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ding Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liang Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hui Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Huijing Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HJW and HZ conceived the idea for the paper. RYL, CX, and QH completed data collection. YDH, RLZ, CX, DY, and LS contributed to data analysis and interpretation. YDH wrote the initial draft; and all authors contributed to critical revision and final approval of the manuscript.

Corresponding authors

Correspondence to Hui Zhou or Huijing Wu.

Ethics declarations

Conflict of interest

None declared.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 55 kb)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, Y., Zeng, R., Xue, C. et al. Involvement of spleen is associated with shorter survival in patients with angioimmunoblastic T cell lymphoma. J Cancer Res Clin Oncol 149, 9721–9726 (2023). https://doi.org/10.1007/s00432-023-04868-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-023-04868-y

Keywords

Search

Navigation